Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents

Science Communicator Platform

Share By

Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents Publisher Pubmed

Khamisipour G¹ ; Jadidiniaragh F^{2, 3, 4} ; Jahromi AS⁵ ; Zandi K⁶ ; Hojjatfarsangi M^{7, 8}

Source: Tumor Biology Published:2016

Abstract

Resistance to chemotherapy agents is a major challenge infront of cancer patient treatment and researchers. It is known that several factors, such as multidrug resistance proteins and ATP-binding cassette families, are cell membrane transporters that can efflux several substrates such as chemotherapy agents from the cell cytoplasm. To reduce the adverse effects of chemotherapy agents, various targeted-based cancer therapy (TBCT) agents have been developed. TBCT has revolutionized cancer treatment, and several agents have shown more specific effects on tumor cells than chemotherapies. Small molecule inhibitors and monoclonal antibodies are specific agents that mostly target tumor cells but have low side effects on normal cells. Although these agents have been very useful for cancer treatment, however, the presence of natural and acquired resistance has blunted the advantages of targeted therapies. Therefore, development of new options might be necessary. A better understanding of tumor cell resistance mechanisms to current treatment agents may provide an appropriate platform for developing and improving new treatment modalities. Therefore, in this review, different mechanisms of tumor cell resistance to chemotherapy drugs and current targeted therapies have been described. © 2016, International Society of Oncology and BioMarkers (ISOBM).

Related Docs

View other Related Docs

1. Sulforaphane in Alternative Cancer Chemotherapy: From Carcinogenesis Suppression to Drug Resistance Reversal, Results in Chemistry (2025)

2. The Use of Nanoparticles As a Promising Therapeutic Approach in Cancer Immunotherapy, Artificial Cells# Nanomedicine and Biotechnology (2016)

3. Nanoparticles and Targeted Drug Delivery in Cancer Therapy, Immunology Letters (2017)

Experts (# of related papers)

View all Related Experts

Fatemeh Atyabi (2)

Samad Farashi Bonab (1)

Other Related Docs

4. Autophagy in the Regulation of Drug Resistance, (2025)

5. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)

6. Current Therapeutic Approaches and Promising Perspectives of Using Bioengineered Peptides in Fighting Chemoresistance in Triple-Negative Breast Cancer, Biochemical Pharmacology (2023)

7. Apigenin in Cancer Therapy: Prevention of Genomic Instability and Anticancer Mechanisms, Clinical and Experimental Pharmacology and Physiology (2023)

8. Inhibition of Cd73 Using Folate Targeted Nanoparticles Carrying Anti-Cd73 Sirna Potentiates Anticancer Efficacy of Dinaciclib, Life Sciences (2020)

9. A Review on Targeting Tumor Microenvironment: The Main Paradigm Shift in the Mab-Based Immunotherapy of Solid Tumors, International Journal of Biological Macromolecules (2022)

10. Recent Advances in Targeting Mtor Signaling Pathway Using Small Molecule Inhibitors, Journal of Drug Targeting (2017)

11. Targeted Cancer Therapy: Review Article, Tehran University Medical Journal (2018)

12. Don't Eat Me/Eat Me Signals As a Novel Strategy in Cancer Immunotherapy, Heliyon (2023)

13. New Emerging Therapeutic Strategies Based on Manipulation of the Redox Regulation Against Therapy Resistance in Cancer, Antioxidants and Redox Signaling (2024)

14. Stimuli-Responsive Mesoporous Silica Nps As Non-Viral Dual Sirna/Chemotherapy Carriers for Triple Negative Breast Cancer, Molecular Therapy Nucleic Acids (2017)

15. Flavonoids Target Different Molecules of Autophagic and Metastatic Pathways in Cancer Cells, Cancer Cell International (2023)

16. The Role of Dna Damage Response in Chemo- and Radio-Resistance of Cancer Cells: Can Ddr Inhibitors Sole the Problem?, DNA Repair (2021)

17. Dual Drug Delivery System of Plga Nanoparticles to Reverse Drug Resistance by Altering Bax/Bcl-2, Journal of Drug Delivery Science and Technology (2018)

18. Lncrna-Mediated Regulation of Cisplatin Response in Breast Cancer, Pathology, research and practice (2024)

19. Paclitaxel Resistance Resulted in a Stem-Like State in Triple-Negative Breast Cancer: A Systems Biology Approach, Meta Gene (2020)

20. Tumor-Associated Macrophages, Nanomedicine and Imaging: The Axis of Success in the Future of Cancer Immunotherapy, Immunotherapy (2017)

Style	Citing Format
MLA	Khamisipour G, et al.. "Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents." Tumor Biology, vol. 37, no. 8, 2016, pp. 10021-10039.
APA	Khamisipour G, Jadidiniaragh F, Jahromi AS, Zandi K, Hojjatfarsangi M (2016). Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents. Tumor Biology, 37(8), 10021-10039.
Chicago	Khamisipour G, Jadidiniaragh F, Jahromi AS, Zandi K, Hojjatfarsangi M. "Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents." Tumor Biology 37, no. 8 (2016): 10021-10039.
Harvard	Khamisipour G et al. (2016) 'Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents', Tumor Biology, 37(8), pp. 10021-10039.
Vancouver	Khamisipour G, Jadidiniaragh F, Jahromi AS, Zandi K, Hojjatfarsangi M. Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents. Tumor Biology. 2016;37(8):10021-10039.
BibTex	@article{ author = {Khamisipour G and Jadidiniaragh F and Jahromi AS and Zandi K and Hojjatfarsangi M}, title = {Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents}, journal = {Tumor Biology}, volume = {37}, number = {8}, pages = {10021-10039}, year = {2016} }
RIS	TY - JOUR AU - Khamisipour G AU - Jadidiniaragh F AU - Jahromi AS AU - Zandi K AU - Hojjatfarsangi M TI - Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents JO - Tumor Biology VL - 37 IS - 8 SP - 10021 EP - 10039 PY - 2016 ER -

Science Communicator Platform

Authors

Abstract